Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model

Background and Aim. Crohn’s disease is associated with gut microbiota (GM) dysbiosis. Treatment with the anti-IL-12p40 monoclonal antibody (12p40-mAb) has therapeutic effect in Crohn’s disease patients. This study addresses whether a 12p40-mAb treatment influences gut microbiota (GM) composition in...

Full description

Saved in:
Bibliographic Details
Main Authors: Josué Castro-Mejía, Maja Jakesevic, Łukasz Krych, Dennis S. Nielsen, Lars H. Hansen, Bodil C. Sondergaard, Peter H. Kvist, Axel K. Hansen, Thomas L. Holm
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2016/4953120
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850161219132981248
author Josué Castro-Mejía
Maja Jakesevic
Łukasz Krych
Dennis S. Nielsen
Lars H. Hansen
Bodil C. Sondergaard
Peter H. Kvist
Axel K. Hansen
Thomas L. Holm
author_facet Josué Castro-Mejía
Maja Jakesevic
Łukasz Krych
Dennis S. Nielsen
Lars H. Hansen
Bodil C. Sondergaard
Peter H. Kvist
Axel K. Hansen
Thomas L. Holm
author_sort Josué Castro-Mejía
collection DOAJ
description Background and Aim. Crohn’s disease is associated with gut microbiota (GM) dysbiosis. Treatment with the anti-IL-12p40 monoclonal antibody (12p40-mAb) has therapeutic effect in Crohn’s disease patients. This study addresses whether a 12p40-mAb treatment influences gut microbiota (GM) composition in mice with adoptive transfer colitis (AdTr-colitis). Methods. AdTr-colitis mice were treated with 12p40-mAb or rat-IgG2a or NaCl from days 21 to 47. Disease was monitored by changes in body weight, stool, endoscopic and histopathology scores, immunohistochemistry, and colonic cytokine/chemokine profiles. GM was characterized through DGGE and 16S rRNA gene-amplicon high-throughput sequencing. Results. Following 12p40-mAb treatment, most clinical and pathological parameters associated with colitis were either reduced or absent. GM was shifted towards a higher Firmicutes-to-Bacteroidetes ratio compared to rat-IgG2a treated mice. Significant correlations between 17 bacterial genera and biological markers were found. The relative abundances of the RF32 order (Alphaproteobacteria) and Akkermansia muciniphila were positively correlated with damaged histopathology and colonic inflammation. Conclusions. Shifts in GM distribution were observed with clinical response to 12p40-mAb treatment, whereas specific GM members correlated with colitis symptoms. Our study implicates that specific changes in GM may be connected with positive clinical outcomes and suggests preventing or correcting GM dysbiosis as a treatment goal in inflammatory bowel disease.
format Article
id doaj-art-fb6f359e86ac4ef189daf717302497dc
institution OA Journals
issn 1687-6121
1687-630X
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-fb6f359e86ac4ef189daf717302497dc2025-08-20T02:22:55ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/49531204953120Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis ModelJosué Castro-Mejía0Maja Jakesevic1Łukasz Krych2Dennis S. Nielsen3Lars H. Hansen4Bodil C. Sondergaard5Peter H. Kvist6Axel K. Hansen7Thomas L. Holm8Department of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg, DenmarkDepartment of Veterinary Disease Biology, Faculty of Health and Medical Science, University of Copenhagen, Thorvaldsensvej 57, 1870 Frederiksberg, DenmarkDepartment of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg, DenmarkDepartment of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg, DenmarkDepartment of Environmental Science, Aarhus University, Frederiksborgvej 399, 4000 Roskilde, DenmarkNovo Nordisk Park, 2760 Maaloev, DenmarkNovo Nordisk Park, 2760 Maaloev, DenmarkDepartment of Veterinary Disease Biology, Faculty of Health and Medical Science, University of Copenhagen, Thorvaldsensvej 57, 1870 Frederiksberg, DenmarkNovo Nordisk Park, 2760 Maaloev, DenmarkBackground and Aim. Crohn’s disease is associated with gut microbiota (GM) dysbiosis. Treatment with the anti-IL-12p40 monoclonal antibody (12p40-mAb) has therapeutic effect in Crohn’s disease patients. This study addresses whether a 12p40-mAb treatment influences gut microbiota (GM) composition in mice with adoptive transfer colitis (AdTr-colitis). Methods. AdTr-colitis mice were treated with 12p40-mAb or rat-IgG2a or NaCl from days 21 to 47. Disease was monitored by changes in body weight, stool, endoscopic and histopathology scores, immunohistochemistry, and colonic cytokine/chemokine profiles. GM was characterized through DGGE and 16S rRNA gene-amplicon high-throughput sequencing. Results. Following 12p40-mAb treatment, most clinical and pathological parameters associated with colitis were either reduced or absent. GM was shifted towards a higher Firmicutes-to-Bacteroidetes ratio compared to rat-IgG2a treated mice. Significant correlations between 17 bacterial genera and biological markers were found. The relative abundances of the RF32 order (Alphaproteobacteria) and Akkermansia muciniphila were positively correlated with damaged histopathology and colonic inflammation. Conclusions. Shifts in GM distribution were observed with clinical response to 12p40-mAb treatment, whereas specific GM members correlated with colitis symptoms. Our study implicates that specific changes in GM may be connected with positive clinical outcomes and suggests preventing or correcting GM dysbiosis as a treatment goal in inflammatory bowel disease.http://dx.doi.org/10.1155/2016/4953120
spellingShingle Josué Castro-Mejía
Maja Jakesevic
Łukasz Krych
Dennis S. Nielsen
Lars H. Hansen
Bodil C. Sondergaard
Peter H. Kvist
Axel K. Hansen
Thomas L. Holm
Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model
Gastroenterology Research and Practice
title Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model
title_full Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model
title_fullStr Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model
title_full_unstemmed Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model
title_short Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model
title_sort treatment with a monoclonal anti il 12p40 antibody induces substantial gut microbiota changes in an experimental colitis model
url http://dx.doi.org/10.1155/2016/4953120
work_keys_str_mv AT josuecastromejia treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT majajakesevic treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT łukaszkrych treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT dennissnielsen treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT larshhansen treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT bodilcsondergaard treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT peterhkvist treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT axelkhansen treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel
AT thomaslholm treatmentwithamonoclonalantiil12p40antibodyinducessubstantialgutmicrobiotachangesinanexperimentalcolitismodel